1. Volume 6, Issue 4, Pages e230-e239 (April 2019)
Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial 
Frances H Priddy, MD, Prof David J M Lewis, MD, Huub C Gelderblom, MD, Hana Hassanin, MD, Claire Streatfield, MPhil, Celia LaBranche, PhD, Jonathan Hare, PhD, Josephine H Cox, PhD, Len Dally, MSc, Daryl Bendel, MD, Prof David Montefiori, PhD, Eddy Sayeed, PhD, Jim Ackland, BSc, Prof Jill Gilmour, PhD, Bruce C Schnepp, PhD, J Fraser Wright, PhD, Philip Johnson, MD 
The Lancet HIV 
Volume 6, Issue 4, Pages e230-e239 (April 2019)
DOI: /S (19)
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

2. Figure 1
Trial profile
The Lancet HIV 2019 6, e230-e239DOI: ( /S (19) )
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

3. Figure 2
Serum PG9 concentration, HIV neutralisation, and presence of confirmed anti-PG9 antibody
Each coloured line corresponds to a different volunteer. – under HIV neutralisation indicates absence and + indicates presence of HIV neutralisation on either a nine-virus pseudovirus panel or to CAP G3 pseudovirus; – under PG9 anti-drug antibody indicates absence and + indicates presence of confirmed tier 2 PG9 anti-drug antibody. Group A=4 × 1012 vector genomes. Group B=4 × 1013 vector genomes. Group C=8 × 1013 vector genomes. Group D and group D1=1·2 × 1014 vector genomes. LLoQ=lower limit of quantification.
The Lancet HIV 2019 6, e230-e239DOI: ( /S (19) )
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

4. Figure 3 Serum AAV1 antibody titres
Each coloured line corresponds to a different volunteer. BC=below cutoff. Group A=4 × 1012 vector genomes. Group B=4 × 1013 vector genomes. Group C=8 × 1013 vector genomes. Group D and group D1=1·2 × 1014 vector genomes. LLoQ=lower limit of quantification.
The Lancet HIV 2019 6, e230-e239DOI: ( /S (19) )
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

5. Figure 4 Quadriceps muscle biopsy staining
(A) Sections from a placebo recipient. (B) Sections from an AAV1-PG9DP recipient from group D1.
The Lancet HIV 2019 6, e230-e239DOI: ( /S (19) )
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions